Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer
about
Role of stromal cell-derived factor 1α pathway in bone metastatic prostate cancerMultimodal imaging guided preclinical trials of vascular targeting in prostate cancer.A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.Evidence for a pro-proliferative feedback loop in prostate cancer: the role of Epac1 and COX-2-dependent pathways.Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.Effects of transdermal testosterone treatment on inflammatory markers in elderly males.Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton.Stromal Androgen Receptor in Prostate Cancer Development and ProgressionRole of inflammasomes and their regulators in prostate cancer initiation, progression and metastasis.NQO1 suppresses NF-κB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis.IL-1β induces p62/SQSTM1 and represses androgen receptor expression in prostate cancer cellsThe fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome.NLRP3 inflammasome activation plays a carcinogenic role through effector cytokine IL-18 in lymphoma.Gonadotropin-releasing hormone analogues lead to pro-inflammatory changes in T lymphocytes.
P2860
Q26741064-42D32949-F316-477A-9C57-8C38B383229DQ30393012-877330D9-69B0-42BC-9347-7C67D3319AEDQ33404541-CD420CB8-CBE6-4E0F-A98C-D6FCB296BCE3Q34707066-AA3F652D-5A3D-45D0-8126-9AA08587AC92Q35764986-B04A1C4E-EF1F-4CED-8C9F-D9761E83A691Q37234333-75D7155B-89FF-44A1-B096-52EE7EC62DB6Q37335554-64DBD0E3-DB23-4D00-88F3-CA8A24B7BD27Q37418939-42771BCC-1B2A-4D4F-AF83-128BA319337DQ37629551-E96E900A-5FF0-42D0-BA3F-D421699461EBQ38116435-611565A7-0842-43A5-AE22-282E47BCE102Q38965814-94797EDD-C236-423A-8CAF-FDB8DA0AF9D5Q38967963-3C7EC019-9984-461C-93A0-33177117A77DQ41582971-D8B46E63-A9CB-4DAF-A601-CBFE552781E8Q49409385-7DD3E2DD-98CC-462F-8130-16DC7C089E4BQ51706575-7AE2475D-32DC-47B7-AC35-DDCBDC2FAE05
P2860
Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Changes in biomarkers of infla ...... on therapy for prostate cancer
@ast
Changes in biomarkers of infla ...... on therapy for prostate cancer
@en
type
label
Changes in biomarkers of infla ...... on therapy for prostate cancer
@ast
Changes in biomarkers of infla ...... on therapy for prostate cancer
@en
prefLabel
Changes in biomarkers of infla ...... on therapy for prostate cancer
@ast
Changes in biomarkers of infla ...... on therapy for prostate cancer
@en
P2093
P2860
P1433
P1476
Changes in biomarkers of infla ...... on therapy for prostate cancer
@en
P2093
Anthony L Zietman
Dan G Duda
Jason A Efstathiou
Kevin R Kozak
Marek A Ancukiewicz
Matthew R Smith
Philip J Saylor
Rakesh K Jain
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0321
P577
2012-02-02T00:00:00Z